GASTROINTESTINAL AND LIVER DISEASE – Exercise 36

The multiple choice questions in this online test paper focuses on GASTROINTESTINAL AND LIVER DISEASE MCQ. If you are looking for self evaluation of your PG Medical entrance exam preparation then this online GASTROINTESTINAL AND LIVER DISEASE MCQ Test Paper will help you to evaluate your exam preparation.

Instruction for REPRODUCTIVE BIOLOGY/ REPRODUCTIVE MEDICINE / INFERTILITY MCQs:

1- This online MCQ practice test paper contains 30 questions.
2- Each question in this online practice test paper have four options and only 1 option is correct.
3- You can view the answers of this practice test paper after submitting the practice test paper.
Note: The answers mentioned at the end of practice test are the best suitable option as per our knowledge. Users shall cross-check the answers with their textbooks.

Q 1. current standard treatment of chronic hepatitis C is

PEG IFN

Ribavarin

PEG IFN +ribavirin

all of the above

Q 2. virus implicated in pathogenesis of autoimmune hepatitis

hepatitis viruses

measles virus

EBV

all of the above

Q 3. standard indication for antiviral therapy of chronic hepatitis C is

detectable HCV RNA (with or without elevated ALT)

portal/bridging fibrosis on liver biopsy

moderate to severe hepatitis on liver biopsy

all of the above

Q 4. in autoimmune hepatitis immunoregulatory dysfunction of which of the following occurs

CD8+CD24+ regulatory T cells

CD8+CD25+ regulatory T cells

CD4+CD24+ regulatory T cells

CD4+CD25+ regulatory T cells

Q 5. rapid virologic response refers to undetectable HCV RNA at what time after institution of therapy

2 weeks

4 weeks

8 weeks

12 weeks

Q 6. autoimmune hepatitis is a

acute hepatitis

subacute hepatitis

chronic hepatitis

any of the above

Q 7. following variables does not correlate favourably in the IFN based treatment of chronic hepatitis C

genotypes 2 and 3

genotypes 1 and 4

low baseline HCV RNA level

histologically mild hepatitis

Q 8. dose of PEG IFN alpha 2b

.5µg/kg weekly subcutaneusly

1.5µg/kg weekly subcutaneusly

2.5µg/kg weekly subcutaneusly

3.5µg/kg weekly subcutaneusly

Q 9. drug beneficial in acute hepatitis C

lamivudine

interferon monotherapy

ribavirin

glucocorticoid

Q 10. false statement regarding anti-SLA

associated with a more severe disease course

present in nonhepatic autoimmune disorders

target of anti-SLA is tRNP

specific serologic marker for autoimmune liver disease

Q 11. following associated with hepatitis C respond to antiviral therapy

essential mixed cryoglobulinemia

porphyria cutanea tarda

lichen planus

all of the above

Q 12. in fulminant hepatitis following has been shown to improve suvival

glucocorticoid therapy

exchange transfusion

prophylactic antibiotic coverage

extracorporeal liver assisted devices

Q 13. which class of serum globulins elevated in autoimmune hepatitis

alpha globulin

beta globulin

gamma globulin

delta globulin

Q 14. responder status is estimated at what time after institution of therapy in hepatitis C

12 weeks

24 weeks

48 weeks

72 weeks

Q 15. drug implicated in pathogenesis of autoimmune hepatitis

minocycline

atorvastatin

interferon

all of the above

Q 16. most pronounced side effect of ribavirin therapy is

seizures

agranulocytosis

hemolysis

all of the above

Q 17. following is advocated in those who have not responded to treatment with PEG IFN/ribavarin in chronic hepatitis C

longer duration of treatment

higher doses of either PEG IFN , ribavirin , or both

switching to a different IFN prepration

all of the above

Q 18. autoantibody present in patients of autoimmune hepatitis

antinuclear antibodies

anti-LKM

antibodies to soluble liver antigen/liver pancreas antigen

all of the above

Q 19. early virologic response estimated at what time after institution of therapy in hepatitis C

2 weeks

4 weeks

8 weeks

12 weeks

Q 20. combination IFN-ribavirin therapy in chronic hepatitis C genotype 2 and 3 should last for

12 weeks

24 weeks

48 weeks

72 weeks

Q 21. following is a laboratory feature of chronic hepatitis C

fluctuating aminotransferase levels

jaundice is rare

circulating anti-LKM1 antibodies

all of the above

Q 22. elimination time of PEG IFN longer than standard IFN by

3 times

5 times

7 times

9 times

Q 23. in acute liver failure all drugs are recommended except

lamivudine

telbivudine

adefovir

entecavir

Q 24. combination IFN-ribavirin therapy in chronic hepatitis C genotype 1 should last for

12 weeks

24 weeks

48 weeks

72 weeks

Q 25. antiviral therapy in chronic hepatitis C patients is not recommended in

Age > 60 years

mild hepatitis on liver biopsy

persons with severe renal insufficiency

all of the above

Q 26. halflife in serum of hepatitis C virion is

2-3 hours

2-3 days

2-3 months

2-3 years

Q 27. extrahepatic manifestation of autoimmune hepatitis include

arthritis

cutaneous vasculitis

glomerulonephritis

all of the above

Q 28. following enhances the efficiency of IFN

ribavirin

adefovir

entecavir

tenofovir

Q 29. sustained virologic response (SVR) is estimated at what time after institution of therapy in hepatitis C

12 weeks

24 weeks

48 weeks

72 weeks

Q 30. interferon therapy in hepatitis C viral infection results in activation of

cytokines

chemokines

JAKSTAT signal transduction pathway

all of the above

GASTROINTESTINAL AND LIVER DISEASE – Exercise 36

pgmedmin

Recent Posts

Categories

GASTROINTESTINAL AND LIVER DISEASE – Exercise 36

pgmedmin

Popular Tags

Recent Posts

Categories